Cytomegalovirus (CMV) infection is the most important cause of mental retardation and sensorineural hearing loss. Antiviral treatment with valganciclovir, a relatively new but potential toxic oral drug, is recommended to prevent further hearing deterioration. In this retrospective cohort study we evaluated the relation between the dose of valganciclovir and the reduction of CMV viral load, as well as the toxicity. All neonates with gestational age <32 weeks with CMV infection treated with oral valganciclovir (30 mg/kg/day) were included. Time interval to reach CMV viral load below detection level (<250 copies/ml) was determined. Toxicity was measured by plasma trough levels, thrombocytopenia and leukopenia. Data of 6 infants, median gestational age 252 weeks, were analyzed. Time interval between start of therapy and viral load below detection level was 25 -54 days. In total, 37 through plasma samples were analyzed. Of these, 28 were in the normal range, 3 above and 6 under the target concentration. Mild transient leukopenia occurred in 1 infant. No thrombocytopenia occurred. Conclusion: Antiviral treatment of CMV infection with oral valganciclovir results in adequate plasma through levels. Also, a progressive reduction of viral load in the urine below detection level was reached within 25 -54 days, without serious short time side effects.
Introduction
Cytomegalovirus (CMV) is a consistent infection worldwide. In adults it is an innocuous infection; in neonates it is an important cause of neonatal morbidity.
CMV infection is the most important cause of mental retardation and sensoriHow to cite this paper: Boesveld [10] . The viral load of CMV can be detected in blood or urine by DNA-polymerase chain reaction (PCR). Boppana et al. [11] and Lanari et al. [12] already demonstrated that a high viral load, as a reflection of high virus activity, is associated with neuro sensorineural hearing loss. Without treatment, children with congenital CMV continue to excrete the virus in the urine for approximately 3 -5 years [7] . Valganciclovir, has the risk of serious toxic side effects including thrombocytopenia and leukocytopenia, therefore determining plasma levels are recommended [7] .
In this study we evaluated the relation between the dose of oral valganciclovir and the reduction of CMV viral load over time in the urine, as well as the toxicity, determined as high valganciclovir plasma trough levels and neutropenia or thrombocytopenia, in infants with a gestational age <32 weeks.
Materials and Methods
We performed a retrospective cohort study in our neonatal intensive care unit 
Subjects
All neonates <32 weeks gestational age treated with oral valganciclovir for CMV infection were included. The diagnosis of CMV was based on a positive urine culture. Exclusion criteria were: congenital anomalies and incomplete data. 
Viral Load
Number of CMV copies/ml were measured in the urine by DNA-realtime PCR (Applied Biosystems ABI 7500), with a ultimate detection level of <250 copies/ml.
Valganciclovir
The initial dosage of oral valganciclovir was 30 mg/kg/day divided in 2 doses, regularly adapted for weight gain and plasma levels. Before starting treatment and subsequently every week plasma levels of valganciclovir (P trough and P peak ) and side effects of treatment such as thrombocytopenia (<100 × 109/L) [13] and leukopenia (<5 × 109/L) were determined in blood required by venous punction.
Platelets and the leukocytes were measured by Sysmex technology. Plasma samples for valganciclovir were obtained at steady state, just before the oral solution (Ptrough) and two hours after administration (Ppeak). The suggested therapeutic range for plasma levels are: Ptrough 0.2 -1 mg/L and Ppeak 2.5 -12.5 mg/L. Blood Samples were centrifuged and serum samples collected and tested immediately using liquod chromatography-mass spectrometry (LC-MS).
Statistical Analysis
Statistical analysis was performed using SPSS software version 22.0. Patient characteristics are described by number and percentage or expressed as median with interquartile range (IQR). The variable pharmacokinetic data is expressed as mean with standard deviation (SD) and median with IQR. The study was approved by the medical ethical committee of our hospital.
Results
During the study period 13 infants were diagnosed with a CMV infection and (Table 1) . Valganciclovir plasma levels were measured regularly ( Table 2 ). In total, 37 trough plasma samples and 2 h plasma samples Table 2 . Valganciclovir plasma levels (P trough and P peak ) of all six infants with CMV infection. were analyzed. Of these 37 trough samples, 28 were in the normal range, 3 above and 6 under the target concentration. Mean P trough concentration was 0.8 µg/ml (±1 SD 0.8 µg/ml) and median P trough concentration was 0.5 µg/ml (IQR: 0.4 -0.9). Mean P peak concentration was 4.2 µg/ml (±1 SD 3.2 µg/ml) and median P peak concentration was 3.5 µg/ml (IQR: 2.5 -4.9). No thrombocytopenia occurred.
Mild leukopenia (leukocytes 4.5 × 109/L) occurred in one infant.
Discussion
This This is important while considering the possibility of expanding the criteria and the duration of treatment with valganciclovir in very premature neonates.
In 2005 Boppana et al. [11] stated that infants with <5 × 103 pfu/mL of urine CMV and infants with <1 × 104 copies/mL of viral DNA in blood plasma were at a lower risk for hearing loss. The study of Lanari et al. [12] showed a negative predictive value of 95% of progressive hearing loss in patients with DNA emia <1000 copies per 105 PMNLs. Recently, Forner et al. [14] , described that infants with a viral load in blood at birth of ≥12,000 copies/mL were more likely to experience CMV-related sequelae and that the risk of hearing deficit increased with a viral load in blood of ≥17,000 copies/mL. Rivera et al. [15] concluded that infants with urine viral load > 50,000 pfu/ ml were at greater risk of hearing loss. Determination of the presumed therapeutic level in urine and blood is an important subject for further research, as well as the target time to decrease the viral load. One can hypothesis that a shorter period of high viral load might reduce the risk of vulnerability of the neonatal brain during a developmental period of rapid cerebral growth regarding volume and connectivity. There is no strong relationship between blood levels of valganciclovir and rate of viral clearance. Besides, antiviral cellular immunity plays an essential role in viral clearance. More research is necessary to determine the dose effect and viral clearance after valganciclovir in very premature infants. In the literature there's agreement to start antiviral treatment in infants with a symptomatic congenital CMV disease [16] , but treatment of asymptomatic congenital or postnatal CMV is still controversial and under debate. Nevertheless, 7.2% -21% infants with an asymptomatic congenital infection will have permanent sequelae, predominantly sensorineural hearing loss [1] [20] . An additional risk of sensorineural hearing loss in this group has not been excluded. Regarding their cerebral developmental stage a postnatal CMV infection in very premature infants shortly after birth might not be unharmful and might face the same consequences as a fetal CMV infection in the second trimester of pregnancy. Based on this assumption and the reported low toxicity of oral valganciclovir, furthermore research might give insight in the potential of valganciclovir treatment in very premature infants with early postnatal infection in relation to the trend of viral load in plasma or urine. Finally, the duration of treatment should be noticed. In the literature most infants are being treated for six weeks [7] [9] [10] , however treatment up to six months is considered in infants with moderately to severe congenital CMV in recent consensus recommendations [4] [21]. In our opinion, the duration of therapy is also dependent on the natural defenses to curb the virus replication or upon the end of the vulnerable period. In this study most infants were treated for 3 months, with a variation between 6 weeks and 6 months. At first, the duration was chosen to gap a vulnerable period of cerebral development and secondly based on the well tolerance of the oral valganciclovir. Both are open for discussion and subject for further research. This study has some limitations to be addressed. At first, it is the small sample size of this single centre study. Furthermore, due to the focus on pharmacotherapeutic issues only short term follow up has been incorporated.
Conclusion
In this study, we showed that antiviral treatment with oral valganciclovir in case of congenital or postnatal acquired CMV infection is safe, even for premature neonates with gestational age <32 weeks. Viral load may be used to measure the pharmacological effectiveness of treatment. Therefore, an extension of the treatment period towards 6 months may safely be introduced while closely monitoring blood parameters and viral load. Future prospective studies evaluating the effect of different dosage regimens on the decrease of viral load and the long term outcome are recommended, also in premature infants treated for CMV infection.
